Steadybase.

Eikon Therapeutics, Inc.

Website Investor relations LinkedIn Latest 10-K
  • EIKN · Nasdaq
  • Biological Products, (No Diagnostic Substances)
  • Millbrae, CA
  • 384 employees
  • CIK 0001861123

Updated from SEC filings through

Top things to know

Executives

Eikon Therapeutics, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Millbrae, CA. It trades as EIKN on Nasdaq. It reported about 384 employees.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Roger M. Perlmutter Roger M. Perlmutter Chief Executive Officer, Chair and Director 10-K, March 30, 2026
Alfred Bowie Chief Financial Officer 10-K, March 30, 2026
Michael Klobuchar Chief Operating Officer 10-K, March 30, 2026
Benjamin Thorner Chief Business Officer and General Counsel 10-K, March 30, 2026
Roy Baynes Chief Medical Officer 10-K, March 30, 2026
David Meline Director 10-K, March 30, 2026
Joshua Wolfe Director 10-K, March 30, 2026
Kenneth C. Frazier Director 10-K, March 30, 2026
Leon Chen Director 10-K, March 30, 2026
Robert Huffines Director 10-K, March 30, 2026

What Eikon Therapeutics, Inc. does

Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers.

Press release "About" paragraph, 10-K for the year ending October 26, 2026

Shares and governance

Shares outstanding 54.2 million (as of November 2, 2026) 10-Q, November 12, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 12, 2026

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
February 4, 2026 Kenneth C. Frazier
Director
Buy 111,111 $2.0M Form 4, February 6, 2026
February 4, 2026 Josh Wolfe
Director
Buy 277,776 $5.0M Form 4, February 6, 2026
February 4, 2026 Josh Wolfe
Director
Buy 277,776 $5.0M Form 4, February 6, 2026

Recent 8-K events

Frequently asked questions about Eikon Therapeutics, Inc.

What does Eikon Therapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers."
How many employees does Eikon Therapeutics, Inc. have?
About 384 as of December 31, 2025, as stated in its annual report.
Who is the CFO of Eikon Therapeutics, Inc.?
Alfred Bowie, Chief Financial Officer, as named in a 10-K filed March 30, 2026.
Where is Eikon Therapeutics, Inc. headquartered?
Millbrae, CA.
What is Eikon Therapeutics, Inc.'s stock ticker?
EIKN on Nasdaq.
What industry is Eikon Therapeutics, Inc. in?
Biological Products, (No Diagnostic Substances), SIC code 2836.
What is Eikon Therapeutics, Inc.'s website?
eikontx.com. Investor relations: https://investors.eikontx.com/.
When does Eikon Therapeutics, Inc. report earnings next?
February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Eikon Therapeutics, Inc. a public company?
Yes. Eikon Therapeutics, Inc. files with the SEC under CIK 0001861123 and trades as EIKN.
How many shares of Eikon Therapeutics, Inc. are outstanding?
54.2 million shares as of November 2, 2026, from its 10-Q filed November 12, 2026.
How many business segments does Eikon Therapeutics, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
Have Eikon Therapeutics, Inc. insiders traded stock recently?
Since February 4, 2026, officers and directors reported 0 open-market sales and 3 purchases worth about $12.0M on Forms 4 and 5. The most recent: Kenneth C. Frazier (Director) bought 111,111 shares on February 4, 2026.